EP1693372A1 — Novel Sulfamides and their use as endothelin receptor antagonists
Assigned to Actelion Pharmaceuticals Ltd · Expires 2006-08-23 · 20y expired
What this patent protects
The invention relates to novel sulfamides of the general formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical composi…
USPTO Abstract
The invention relates to novel sulfamides of the general formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.
Drugs covered by this patent
- Opsumit (MACITENTAN) · AstraZeneca
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.